A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

NCT03681184 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperoxaluria Type 1 (PH1)

Interventions

DRUG: Placebo
DRUG: Lumasiran

Sponsor

Alnylam Pharmaceuticals